SA
MNTA

Sicart Associates’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Sicart Associates’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-20,000
Closed -$279K – 101
2017
Q4 		$279K Buy
+20,000
New +$270K 0.15% 92

Other funds holding MNTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sicart Associates's MNTA Position: Q1 2018 in Review

Sicart Associates sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q1 2018, closing a stake of 20,000 shares — an estimated $279K sold.

Sicart Associates first reported a position in MNTA in Q4 2017 and held it in 1 quarter. The position peaked at $279K in Q4 2017. 163 funds tracked by Wall St. Rank hold MNTA as of Q1 2018.

  • Sicart Associates reported no remaining Momenta Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Sicart Associates sold 20,000 Momenta Pharmaceuticals, Inc. shares in Q1 2018, an estimated $279K.
  • Sicart Associates first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2017 and held it in 1 quarter.
  • Sicart Associates's Momenta Pharmaceuticals, Inc. position peaked at $279K in Q4 2017.
  • 163 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q1 2018.

Based on Sicart Associates's 13F filing for Q1 2018, filed 12 Apr 2018.